ERBB2 and cancer: Ganetespib is a second-generation HSP90 inhibitor that destabilizes the oncogenic client proteins of HSP90 critical for signal transduction, promoting cancer cell survival and proliferation, including tyrosine kinases, HER2, and mutant p53 [90].